C
CARsgen Therapeutics
A leading immunotherapy company focused on the development of new chimeric antigen receptor
About CARsgen Therapeutics
CARsgen is a biopharmaceutical company with operations in China and the U.S., specializing in innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors. The company focuses on developing cutting-edge CAR T technologies to create a differentiated product pipeline aimed at making cancer curable. CARsgen serves patients with cancer, particularly those with hematologic malignancies and solid tumors, by providing advanced cell therapies. The company operates in the global biopharmaceutical market and generates revenue through the clinical trials and commercialization of its CAR T cell products. CARsgen has established a strong global presence with vertically integrated manufacturing capabilities, including the production of plasmids, lentiviral vectors, and CAR T cells. The company supports clinical trials and commercialization from its facilities in Shanghai, China, and collaborates with a diverse team of experts across borders to advance its mission. Listed on the Hong Kong Exchanges and Clearing Limited (HKEX) under stock code 2171, CARsgen continues to expand its global manufacturing capacity to meet the needs of cancer patients worldwide.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2014
- Headquarters
- Xuhui District, China
- Listing
- IPO 2021
- Employees
- 85
- Open positions
- 35
- Dealroom signal
- 66.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Oncology, Neurology, Health Diagnostics, Spinout, Biotech and Pharma, medical testing, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | May 2026 | $0 | — | Undisclosed | ↗ |
| IPOOther financing | Jun 2021 | $400M | $400M | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $17M | 0% | −$28M | -163.6% |
| 2025 | $17M | +218.8% | −$28M | -163.6% |
| 2024 | $5.4M | — | −$72M | -1327.7% |
| 2023 | $0 | — | −$90M | — |
| 2022 | $0 | -100% | −$109M | — |
| 2021 | $3.5M | — | −$71M | -2006.3% |
| 2020 | $0 | — | −$39M | — |
Growth signals
Latest recorded traffic for CARsgen Therapeutics is 5.9K monthly website visits, up 73.5% over the last three months. CARsgen Therapeutics's team declined 7.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
BVCF
KTB Ventures
Photon Fund
Series B and later5 investors entered at this stage
Loyal Valley Capital
Lilly Asia Ventures
Summer Capital
Shiyu Capital
South China Venture Capital
Other known investors2 additional known investors
Shanghai Cancer Institute
Shanghai Jiao Tong University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CARsgen Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CARsgen Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.